ArticleBiologics : targets & therapy2018

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.

Yusuf Yazici et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.